inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on: * positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or * bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. 4. patients with moderate or severe form of disease (t \> 38.0°c; respiratory rate (rr) \>22 / min; sp02 \<95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). 5. patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. 6. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. 7. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: * temperature increase; * dry cough or cough with little phlegm; * shortness of breath; * myalgia; * fatigue; * feeling of congestion in the chest; * reduced sense of smell and / or taste. 8. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 9. consent to use reliable method of contraception throughout the study period. 10. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on: * positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or * bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. 4. patients with moderate or severe form of disease (t \> 38.0°c; respiratory rate (rr) \>22 / min; sp02 \<95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). 5. patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. 6. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. 7. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: * temperature increase; * dry cough or cough with little phlegm; * shortness of breath; * myalgia; * fatigue; * feeling of congestion in the chest; * reduced sense of smell and / or taste. 8. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 9. consent to use reliable method of contraception throughout the study period. 10. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: signed informed consent form. patients of both sexes aged 18 to 75 years inclusive. diagnosed covid-19 based on: positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. patients with moderate or severe form of disease (t > 38.0°c; respiratory rate (rr) >22 / min; sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: temperature increase; dry cough or cough with little phlegm; shortness of breath; myalgia; fatigue; feeling of congestion in the chest; reduced sense of smell and / or taste. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. consent to use reliable method of contraception throughout the study period. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: signed informed consent form. patients of both sexes aged 18 to 75 years inclusive. diagnosed covid-19 based on: positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. patients with moderate or severe form of disease (t > 38.0°c; respiratory rate (rr) >22 / min; sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: temperature increase; dry cough or cough with little phlegm; shortness of breath; myalgia; fatigue; feeling of congestion in the chest; reduced sense of smell and / or taste. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. consent to use reliable method of contraception throughout the study period. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on: - positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or - bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. 4. patients with moderate or severe form of disease (t > 38.0°c; respiratory rate (rr) >22 / min; sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). 5. patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. 6. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. 7. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: - temperature increase; - dry cough or cough with little phlegm; - shortness of breath; - myalgia; - fatigue; - feeling of congestion in the chest; - reduced sense of smell and / or taste. 8. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 9. consent to use reliable method of contraception throughout the study period. 10. patients who are able to understand and comply with treatment and procedures during the study.

inclusion criteria: 1. signed informed consent form. 2. patients of both sexes aged 18 to 75 years inclusive. 3. diagnosed covid-19 based on: - positive laboratory tests confirming the sars-cov-2 presence, performed no earlier than 14 days before hospitalization. it is allowed to determine the sars-cov-2 by the pcr or by another method according to the moh temporary guidelines; and / or - bilateral alterations in lungs, typical for covid-19, according to ct scan of the chest. 4. patients with moderate or severe form of disease (t > 38.0°c; respiratory rate (rr) >22 / min; sp02 <95%) not requiring non-invasive / invasive ventilation and / or high-flow oxygenation (hfnt), and / or extracorporeal membrane oxygenation (emo) at the time of screening and randomization (based on the moh temporary guidelines). 5. patients requiring oxygen therapy (oxygenation through a nasal cannula, a simple facemask or other similar oxygen delivery device) with a category "4" according to the who scale. 6. time from hospitalization to the first drug administration should not exceed 48 hours. this item is to be assessed only when re-evaluating the inclusion / exclusion criteria at the randomization visit and treatment initiation. 7. disease duration is no more than 7 full days since the moment of appearing one or more of the symptoms below until the first dose of the drug administration: - temperature increase; - dry cough or cough with little phlegm; - shortness of breath; - myalgia; - fatigue; - feeling of congestion in the chest; - reduced sense of smell and / or taste. 8. for women only: negative pregnancy test result. pregnancy testing is not required for women of not childbearing potential (woncbp): women who are in menopause (defined as an absence of menstruation for at least 2 years or more), or women who undergone surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation), or women with a clinical diagnosis of "infertility". the presence of surgical sterilization and infertility should be confirmed by patient's claim or by relevant document confirming this condition. 9. consent to use reliable method of contraception throughout the study period. 10. patients who are able to understand and comply with treatment and procedures during the study.